The presence of a high amount of PD-L1 in tumor cells represents a key factor in the establishment of both a smart targeting tool for cancer diagnosis and a strategy for cancer therapy; thus, targeting PD-L1 has become one of the most studied areas in cancer immunotherapy. This evidence concerns the gene CD274 and neoplasm.